The role of bone biopsy in clinical practice and research. Sur-vides information on the type of renal osteodystrophy, vival rates of patients on dialysis have increased with improved the degree of severity of the lesions, and the presence dialytic therapy. However, the resultant increased duration of and amount of aluminum deposition in bone [1].
recently, the methods of in situ hybridization histochempredominant hyperparathyroid bone disease, low turnover istry and immunohistochemistry are providing the means bone disease (including osteomalacia and adynamic bone disto study local biomolecules that play a role in bone meease), and mixed uremic osteodystrophy. Serum PTH levels tabolism.
are commonly used to assess bone turnover in dialyzed patients. However, a recent study in our laboratory found that serum This article discusses the types and evolution of renal PTH levels between 65 and 450 pg/ml seen in the majority osteodystrophy, presents an overview of bone biopsy of dialysis patients are not predictive of the underlying bone techniques, discusses clinical applications of bone biopsy, disease. To date, bone biopsy is the most powerful and informaand reviews the research implications of in situ hybridizative diagnostic tool to provide important information on pretion histochemistry and immunohistochemistry.
cisely the type of renal osteodystrophy affecting patients, the degree of severity of the lesions, and the presence and amount of aluminum deposition in bone. Bone biopsy is not only useful in clinical settings but also in research to assess the effects of
TYPES OF RENAL OSTEODYSTROPHY
new therapies on bone. The methods of in situ hybridization Despite a mostly common initial pathogenetic pathhistochemistry (ISHH) and immunohistochemistry (IHC) are way, renal osteodystrophy is not a uniform bone disease.
providing the means to study local biomolecules that play a role in bone metabolism. As these research tools become more
The forms of renal osteodystrophy consist of predomirefined, they will become increasingly valuable in the study of nant hyperparathyroid bone disease, low turnover bone bone. Alternatives to the bone biopsy continue to be pursued, disease, including osteomalacia and adynamic bone disbut they have not been proven to have the same specificity or ease, and mixed uremic osteodystrophy. Transformation sensitivity to effectively determine the potential value of a from one form to another can occur [2] . specific therapeutic regimen.
Predominant hyperparathyroid bone disease
Predominant hyperparathyroid bone disease (PHBD) Renal failure produces changes in mineral metabolism that affect bone structure, turnover, and cellular characis characterized by a marked increase in bone turnover. teristics. When patients reach end-stage renal failure and Irregularly shaped trabecules display numerous abnorrequire chronic maintenance dialysis, nearly all of them mal remodeling sites (Fig. 1) , and an unusually high numhave abnormal bone histology. Improved dialytic therber of bone cells are irregular in arrangement and shape. apy has increased survival rates of patients on dialysis, Deep, irregular resorption cavities often dissect or tunnel but the resultant increased duration of dialysis has led the trabecules. Numerous enlarged osteoclasts contain to a rise in renal osteodystrophy, a metabolic bone dismultiple nuclei with prominent nucleoli. Osteoblast shape ease that can produce fractures, bone pain, and deformichanges from cuboidal to polygonal or spindle shaped. ties late in the course of the disease. Therefore, preven-
The usual palisade-like monolayer of osteoblasts can be tion of renal osteodystrophy is critical. To date, bone replaced by atypical multilayered arrangements of cells biopsy is the most informative diagnostic tool and prowith variable orientation toward the bone surface (from parallel to perpendicular). Osteoid surface and volume increase, and an osteoid seam can thicken because of Usually, only a few thin single labels of tetracycline are sis replaces bone marrow entirely, reflecting the irregular observed. Other characteristics include predominantly activity of osteoblasts in which the regular activity of lamellar bone structure, few active bone formation sites, individual cells is decreased. Numerous irregular osteoand markedly reduced mineralizing surfaces. cytic lacunae within woven osteoid and mineralized bone This type has two subgroups: osteomalacia (LTOM) result from the increased number of osteoblasts enand adynamic renal bone disease (ABD). LTOM is chartrapped in bone, and the mineral apposition rate and acterized by an accumulation of unmineralized matrix the extent and number of mineralizing sites are notably in which a diminution in mineralization precedes or is increased. Findings of thick osteoid seams and diffuse, more pronounced than the inhibition of collagen deposiirregular tetracycline uptake in woven bone are sometion (Fig. 2) . In LTOM, unmineralized bone makes up a times mistakenly diagnosed as osteomalacia. sizable portion of trabecular bone volume. The increased A marked increase in bone turnover often leads to lamellar osteoid volume results from the presence of cancellization of the cortical bone. This causes a net wide osteoid seams that cover much of the trabecular decrease in cortical bone volume most evident in the surface. The occasional presence of woven bone buried appendicular skeleton. PHBD usually presents with high within the trabeculae indicates past high bone turnover. bone volume, but malnutrition, immobilization, or other
Osteoclasts, when present, are usually seen within tracauses can markedly reduce bone volume. Also, areas becular bone or at the small fraction of trabecular surface of high bone mass may be adjacent to pseudocysts conleft without osteoid coating. With ABD, bone volume sisting primarily of hyperplastic or fibrotic bone marrow.
is frequently reduced. Reduced mineralization is coupled In any case, bone strength cannot be equated with high with a parallel decrease in bone formation. ABD is charbone volume in PHBD patients because the irregular acterized by few osteoid seams (Fig. 3 ). trabeculae may lose their proper three-dimensional architecture and connectivity. Also, the poorly mineralized Mixed uremic osteodystrophy trabeculae consist mainly of mechanically deficient woMixed uremic osteodystrophy (MUO) is caused priven bone with a propensity to fracture. This disease marily by defective mineralization with or without increates a particularly fragile, fracture-prone bone; thus, creased bone formation and by increased parathyroid the use of the term "osteosclerosis" is inappropriate.
hormone activity on bone, features that may coexist in varying degrees in different patients. Bone volume/tissue Low turnover bone disease volume is extremely variable and depends on a dominant Representing the other end of the spectrum from pathogenic cause. Other features include increased num-PHBD, low turnover uremic osteodystrophy is marked bers of heterogeneous remodeling sites and usually an by a profound decrease in active remodeling sites. Cerincrease in osteoclasts. Active foci with numerous cells, tain features reflect a marked decrease in osteoblastic peritrabecular fibrosis, and woven osteoid seams coexist with adjacent lamellar sites with a more reduced activity. activity and there are few osteoclasts and osteoblasts. son-Goldner stain, ϫ125 magnification).
Therefore, greater production of lamellar or woven osteoid causes the accumulation of osteoid with normal or pattern of renal osteodystrophy in 2248 patients over 13 years (from 1983 to 1995) , distribution of the four increased thickness of osteoid seams (Fig. 4) . Although active mineralizing surfaces are often present in woven histologic forms varied [3] . MUO was found in the majority of patients over the years, but a slight decrease was bone with higher mineralization rate and diffuse labeling, mineralization surfaces may be low in lamellar bone with seen in 1990 and 1995. PHBD was observed in a large number of patients in 1983, but decreased constantly a low mineral apposition rate.
until 1988, then increased gradually to reach a level in Evolution of renal osteodystrophy 1995 similar to the one found in 1983. LTOM incidence decreased progressively over the 13 years of the survey. In the past, diversity in bone lesions was partly attributed to aluminum toxicity in bone. The major sources
The number of patients with ABD, which was first diagnosed in 1984 increased until the late 1980s, then stayed of contamination in end-stage renal disease (ESRD) patients are aluminum-containing phosphate binders and approximately the same. The trends for patients on hemodialysis and peritoneal dialysis were similar for the high aluminum content of water and dialysate. High morbidity and mortality accompany severe aluminum intoxifour histologic groups. However, peritoneal dialysis patients consistently exhibited more histologic signs of cation, and deferoxamine (DFO) chelation, though efficient, is not without risks. Therefore, efforts were made ABD and fewer signs of PHBD than did hemodialysis patients. to develop tests capable of diagnosing this disease. Determining serum levels of aluminum before and after Between 1983 and 1984, the number of biopsied patients positive for aluminum increased from approxi-DFO treatment, alone or in association with serum PTH, proved useful, but only in those patients with high basemately 40% to approximately 60%, remained stable until 1992, then tended to decrease. In 1995, however, approxline serum aluminum levels who showed a marked increase after DFO challenge and had low serum PTH imately 25% of the biopsies analyzed still showed aluminum in bone. Patients with low bone turnover, either levels. Therefore, bone biopsies were the only unequivocal means to establish aluminum accumulation in bone LTOM or ABD, showed higher aluminum deposition than patients with other forms of renal osteodystrophy, and determine the type of renal osteodystrophy.
Today, aluminum dialysate content is under better and this did not change with time. More patients with stainable aluminum Ͼ 30% were in the LTOM, ABD, control, and aluminum-containing phosphate binders have largely been replaced with calcium salts. To overand MUO groups than in the PHBD group. From 1984 to 1995, bone aluminum accumulation decreased within come parathyroid gland overactivity, therapeutic regimens ensuring better control of serum calcium and phoseach histologic group, and in 1995 aluminum accumulation was mostly seen in patients with MUO and ABD. phorus levels and correction of calcitriol deficiency are also widely used.
In spite of recent strategies, however, aluminum accumulation has not completely disappeared, and dialyzed In a previous study in which we analyzed the changing
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patients still present with PHBD, MUO, and ABD. Revertical or superior biopsies of the anterior iliac crest result in very small morbidity and no mortality as a cent evidence shows that low bone turnover has both histologic and clinical relevance. Patients with this abnorresult of the procedure [4] . The operator's experience is important in minimizing morbidity and in obtaining an mality were found to have abnormal calcium homeostasis, higher incidence of fractures, more bone pain, deadequate specimen. Use of recently developed techniques should further decrease any complications. Palayed healing, and higher morbidity and mortality than did patients exhibiting other histologic abnormalities.
tient reports of pain range from none to moderate and rarely severe.
BONE BIOPSY TECHNIQUES Qualitative and quantitative evaluation of bone Prerequisites for bone biopsies: Bone labeling
Qualitative and quantitative evaluations of the bone sample constitute the final steps in processing a bone The first prerequisite for an informative bone biopsy is proper in vivo labeling with specific, nontoxic, timebiopsy. Qualitative assessment consists of such factors as the suitability of a biopsy for morphometric analysis, spaced bone markers before the biopsy. Antibiotics from the tetracycline family are used because they have sponthe amount of sample needed, where histologic structures should be measured, and what elements to evalutaneous fluorescence and bind to actively forming bone surfaces. With labeling, the level of bone turnover and ate. With quantitative evaluation, numerical values are assigned to the various elements constituting bone [5] . rate of bone formation can be determined, and possible mineralization abnormalities can be identified. A double Potential differences between groups of patients or normal individuals or changes occurring after treatment can labeling technique is best, although the schedule is somewhat more complicated for patients than one prolonged then be statistically evaluated. Compared to earlier techniques for statistical evaluation, the semiautomatic comsingle administration. In most cases, the first label is administered for 2 days followed by an 8-to 15-day free puterized method introduced by Malluche et al [6] interval. Anything fewer than 8 days lessens the distincgreatly reduced the time required to measure surface, tion between labels, particularly in the case of a mineralthickness, volume, and profile count of bone. Software ization defect. Anything more than 15 days may artifiprograms developed for use with the semiautomatic cially increase the number of single labels because the method are all reliable for calculating areas and counts, number of forming sites being completed or started will but some differences exist in computation of lengths, probably increase. During the 2-4 days after the free thus affecting all parameters. Advantages to the compuinterval, the patient takes a second course of antibiotics.
terized-assisted histomorphometric analysis of bone also Bone biopsy is then performed 4-6 days after the last include many means of data verification, and the data administration of tetracycline. During this delay, the tetobtained can be automatically transferred to any statistiracycline becomes slightly buried within mineralized oscal software, thus avoiding entry error. teoid and thus does not leach out. In an emergency, Fully automated image analyzers are available greatly labeling can be shortened to a 1-day-on, 6-days-off and reducing the time required to evaluate bone slides. Al-1-day-on schedule with a single dose of oral tetracycline though they assess parameters of bone structure, they per day (1.0-1.5 g of tetracycline or 600-900 mg of Declo-
are not yet reliable in discriminating such elements as mycin). Gastrointestinal side effects may be greater cellular details, detecting woven vs. lamellar bone, and with this approach. Using two labels with different colors recognizing erosion surface. However, complete autoassures accurate assessment of the mineralization rate. matic analysis of bone may be possible in the future, Tetracycline hydrochloride has a light yellow and dewith improved video cameras, staining techniques, and meclocycline hydrochloride (Declomycin) a yellowcomputerized image-analysis capabilities. orange fluorescence. With the use of only one type of tetracycline, the two labels can merge in states of low CLINICAL APPLICATIONS bone turnover and be unrecognizable as a double label.
Nephrologists must determine a patient's level of bone For patients with normal renal function, dosages of tetraturnover to apply the correct therapy. Serum PTH levels cycline hydrochloride and Declomycin are usually 500 measured with radioimmunometric assay are commonly mg and 300 mg t.i.d., respectively. For patients with imused to assess bone turnover in dialyzed patients. Alpaired renal function, dosages should be reduced to 500 though these levels have been found to be more sensitive mg and 300 mg b.i.d.
than the previously employed radioimmunoassays, at Potential complications of bone biopsies present there is no consensus regarding the serum level of PTH that reflects normal bone turnover in ESRD Complications from bone biopsies can include pain, patients. A recent study in our laboratory found that hematoma, wound infection, and rarely neuropathy. However, studies show that horizontal or transiliac and serum PTH levels between 65 and 450 pg/ml, seen in the S-24 majority of dialysis patients, are not predictive of the to assess in different laboratories, and low levels of RNA gene expression may escape detection if the correspondunderlying bone disease [7] . Because bone biopsies provide a sensitive measurement of bone changes, they more ing autoradiographic signal is dispersed over a large surface of the section or is masked by background. Thereaccurately determine the type of renal osteodystrophy and can indicate potential aluminum accumulation in fore, caution must be used before important biological conclusions are drawn from negative results. Finally, dialyzed patients [8] . Bone biopsies also allow tailored therapeutic measures. The extent of aluminum deposits specificity relies on the choice of suitable sequences of probe and stringency adopted for the hybridization proat the bone-osteoid interface and the level of bone turnover determine the optimal duration of chelation therapy.
cedure. Moreover, ISHH reveals only intracellular RNA transcripts and does not provide information about the If the biopsy shows no significant deposits of aluminum, the degree of bone turnover will help the pracsubsequent steps of protein synthesis and extracellular secretion unless associated with immunohistochemistry. titioner determine the route, aggressiveness, and length of calcitriol therapy. Severe hyperparathyroidism with Immunohistochemistry marked bone marrow fibrosis is an indication for high doses of intravenous calcitriol if the calcium phosphorus IHC is highly complementary to ISHH in that it links the transcriptional and translational mechanisms of cells. product can be controlled. A bone biopsy can predict whether there will be high resistance to intravenous IHC assesses the metabolic state of bone cells by visualizing protein production. Although the technique of IHC calcitriol at the needed massive doses. In this case, parathyroidectomy may be necessary. The severity of the is well established in soft tissue, its use with hard tissue such as bone is relatively new. Therefore, researchers effect of secondary hyperparathyroidism on bone may also indicate the extent of the post-parathyroidectomy using IHC must be particularly careful to ensure a reliable and reproducible outcome. "hungry bone syndrome" and allow preventive measures such as the preoperative injection of calcitriol. In patients Information derived from molecular histology with mild to moderate increase in bone turnover with
Researchers have demonstrated that factors believed or without mineralization defect, doses of intravenous to play important roles in regulating bone turnover are or preoperative calcitriol and duration of therapy may expressed in bone cells. ISHH has documented expresbe adjusted to avoid the development of ABD. In case sion of bone matrix proteins, including type I collagen, of ABD, calcitriol therapy is not desirable because of osteocalcin, and osteopontin. These proteins are associthe risk of inducing hypercalcemia and extraosseous calated with cell-to-cell and cell-to-mineralized matrix adcifications.
hesion. ISHH has also documented changes in biological A bone biopsy establishes the precise relationships activity measured by type I collagen and osteopontin between serum indices of calcium metabolism and bone mRNA expression in bone cells. The vitamin D receptor, lesions. This enhances the interpretation of longitudinal which plays an important role in regulating bone turnfollow-up of noninvasive parameters while the patient over, has been shown to be expressed in bone cells is undergoing a particular therapy.
through ISHH. Recently, we used histomorphometric and ISHH tech-MOLECULAR BONE HISTOLOGY niques to document expressions of the cytokine interleuIn situ hybridization histochemistry (ISHH) and imkin-6 (IL-6) and its receptor IL-6R in renal osteodystromunohistochemistry (IHC) are two powerful methodolphy patients. IL-6 is believed to be a significant factor ogies used to investigate bone cell metabolism.
in bone remodeling. Our findings indicate that IL-6 and IL-6R are intricately involved in osteoclastic bone reIn situ hybridization histochemistry sorption [9] . Using complementary RNA probes labeled with a reAlthough molecular histology is still in its beginnings, porter molecule, ISHH can detect cellular nucleic acids, its value has been clearly established. The continuing and therefore reveals cellular sources and differential development of more efficient, economical methods will gene expressions of specific biomolecules involved in lead to its routine use as a morphological tool in the bone metabolism, i.e., cytokines, matrix proteins, and study of bone. receptor species. When applied to undecalcified bone section, ISHH can evaluate the relationship between CONCLUSIONS gene expression and cell number and activity in the bone microenvironment.
Bone biopsies are presently much more widely used for diagnosis and research than they have been in the Despite the invaluable information it provides, ISHH also has several limits that must be kept in mind when past. However, traditional constraints continue to be perceived because of the procedure's invasiveness and cost, interpreting results. The sensitivity of ISHH is difficult
